CSAAI 2022 A Midsummer Night’s Wheeze

Sonoma, CA US
July 8, 2022 to July 10, 2022

It is an exciting time in the field of allergy and immunology. This CME program is designed to allow attendees to continue exploring the field. Covered topics include oral food challenges and novel food allergy therapies, contact dermatitis, asthma and biologics, and more!

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunolgy and  California Society of Allergy, Asthma & Immunology (CSAAI). The American College of Allergy, Asthma & Immunolgy is accredited by the ACCME to provide continuing medical education for physicians.”

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 10.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity

CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 10.5 contact hours.

Commercial Support
This activity is supported in part by independent medical education grants from Stallergenes Greer, CSL Behring and BioCryst.

Target Audience

Practicing allergists
Allied health professionals

Learning Objectives

Upon completion of this activity the participant should be able to:

At the conclusion of this activity, participants should be able to:
• Describe signaling pathways and their clinical implications in atopic dermatitis
• Outline an endotype, phenotype and guideline-based approach to the treatment of asthma
• Discuss strategies to overcome COVID-19 vaccine misinformation and hesitancy
• Diagnose and manage eosinophilic gastrointestinal disorders
• Diagnose and manage non IgE-mediated drug allergy
• Diagnose and manage hereditary angioedema
• Diagnose and manage chronic urticaria
• Discuss current and future allergy immunotherapy treatment options for respiratory
allergies
• Outline an approach to the use of biologics for allergic diseases, including asthma, chronic
urticaria and atopic dermatitis
• Evaluate for potential immunodeficiency
• Discuss the “long COVID-19 syndrome”

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 10.50 AMA PRA Category 1 Credit™
  • 10.50 Attendance
  • 10.50 CBRN
Course opens: 
07/10/2022
Course expires: 
07/10/2023
Event starts: 
07/08/2022 - 1:00pm CDT
Event ends: 
07/10/2022 - 12:00pm CDT
Rating: 
0
The Fairmont Sonoma Mission
100 Boyes Blvd.
Sonoma, CA 95476
United States

All identified relevant financial relationships have been mitigated.

Jonathan Bernstein, MD - Speaker
Advisor: AstraZeneca, Sanofi Regeneron, Novartis, Genentech, CSL Behring, Takeda/Shire, BioCryst, Pharming, GSK, Allakos
Speaker: AstraZeneca, Sanofi Regeneron, Novartis, Genentech, CSL Behring, Takeda/Shire, BioCryst, Pharming, GSK, Optinose
Independent contractor: AstraZeneca, Sanofi Regeneron, Novartis, Genentech, CSL Behring, Takeda/Shire, BioCryst, Pharming, GSK, Allakos

J. Andrew Bird, MD - Speaker

Independent contractor: DBV Technologies, Aimmune
Consultant: DBV Technologies

Luz Fonacier, MD - Speaker
Advisor: Pfizer, AbbVie, Lilly
Independent contractor: Pfizer

Madeleine Ramos, MD – Planner
Advisor: Regeneron

Barbara Ariue, MD – Moderator, Planner
Consultant: Regeneron

Raffi Tachdjian, MD – Planner
Speaker: Takeda, CSL Behring, Pharming, BioCryst, Sanofi, GSK, Amgen
Independent contractor: Takeda, CSL Behring, Pharming, BioCryst

Sonal R. Patel, MD – Planner
Speaker: Sanofi/Regeneron

The following have no relevant financial relationships to disclose:
Kimberly G. Blumenthal, MD - Speaker

Warner Carr, MD - Speaker
Anil Nanda, MD - Speaker
Cindy Nguyen, DO - Speaker
Kevin Pedrotti - Speaker
Nina Sadigh, MD - Speaker
LanAnh Do, MD – Moderator, Planner
Marilyn Li, MD – Moderator, Planner
Vincent Tubioli, MD – Planner
Steven Meltzer, MD – Planner
Javed Sheikh, MD – Planner
Myngoc Nguyen, MD – Planner
Karol Anderson – Planner
 

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Eastern Allergy Conference (CSAAI).  The American College of Allergy, Asthma and Immunology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology designates this live activity for a maximum of 14 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 10.50 AMA PRA Category 1 Credit™
  • 10.50 Attendance
  • 10.50 CBRN
Please login or create an account to take this course.